Key result
Aspirin linked to lower VTE and in-hospital mortality without increased bleeding in older cancer patients.
Why the study?
Older patients with cancer have high risks of venous thromboembolism and bleeding, but whether aspirin is associated with reduced VTE in this population was unknown.
Does aspirin reduce venous thromboembolism in older patients with cancer?
Observational
Does aspirin reduce venous thromboembolism in older patients with cancer?
Aspirin use in older cancer patients is associated with lower VTE incidence and inhospital mortality without significantly increasing bleeding risk.
Hypothesis-generating for VTE prophylaxis in older cancer patients; prospective RCTs needed before clinical adoption.
BACKGROUND: Older patients with cancer are at high risk of developing venous thromboembolism (VTE) and bleeding. Aspirin may decrease VTE in the general population without significant bleeding. Here, we examined whether aspirin is associated with reduced rates of VTE in older patients with cancer. METHODS AND In subgroup analyses, aspirin was associated with decreased inhospital mortality, mostly in patients with lung, colon, pancreatic, prostate, breast cancer, lymphoma, and leukemia. CONCLUSIONS: Among older patients with cancer, aspirin was associated with lower VTE incidence and overall inhospital mortality without significantly increased bleeding.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) conducted an observational in Cancer. Aspirin was evaluated on Venous thromboembolism (VTE) incidence. Aspirin was associated with lower venous thromboembolism incidence and overall inhospital mortality without significantly increased bleeding among older patients with cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: